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Abstract
Background: Many resource-limited countries are scaling up antiretroviral treatment (ART) towards universal
access. However, there are few studies which evaluated outcomes of ART programs in these countries. In addition,
these studies generally include a limited number of facilities and patients creating a clear need for studies with a
wide range of facilities and large numbers of patients. In this study, we intended to evaluate the outcomes of the
ART services in 55 health facilities in Ethiopia.
Methods: A retrospective longitudinal study was conducted to determine levels of patient retention in care, CD4
count and shift to second-line ART regimen in 30 hospitals and 25 health centers selected as sentinel sites for
monitoring the outcomes of ART program in the country. The outcomes were determined at baseline, after 6, 12
and 24 months on ART. Data was collected from routine patient registers and charts, and entered and analyzed
using EPI-Info statistical software.
Results: Health facilities were able to retain 29,893 (80%), 20,079 (74%) and 5,069 (68%) of their patients after 6, 12
and 24 months on ART, respectively. Retention rates vary across health facilities, ranging from 51% to 85% after 24
months on ART. Mortality was 5%, 6% and 8% after 6, 12 and 24 months on ART. More than 79% of patients with
available CD4-cell counts had a baseline CD4-cell counts less than 200 cells per micro-liter of blood. The median
CD4-cell counts (based on patients who were retained after 24 months on ART) increased from 125 (inter-quartile
(IQ), 68-189) at baseline to 242 (IQ, 161-343), 269 (IQ, 185-380) and 316 (IQ, 226-445) cells per micro-liter after 6, 12,
and 24 months on ART, respectively. The transition to second-line ART remained very low, 0.33%, 0.58% and 2.13%
after 6, 12 and 24 months on ART.
Conclusion: The outcomes of the ART services in the 55 health facilities in Ethiopia are similar to those in other
countries. Retention of patients in care is a major challenge and varies across health facilities with high, medium
and low retention rates. We therefore recommend further studies to understand the organization of care in
health facilities with high, medium and low retention rates. It is also imperative that early initiation of patients
on ART is taken seriously as more than 79% of the patients had baseline CD4-cell counts less than 200 cells per
micro-liter of blood. Finally, we recommend that the shift to second-line ART might be too low and warrants
close monitoring.
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The use of antiretroviral treatment (ART) has substan-
tially decreased morbidity and mortality in people living
with HIV/AIDS (PLwHAs) [1-3]. As a result, there have
been several initiatives for the rapid scale-up of ART in
resource-limited countries (RLCs). Some of these initia-
tives are: (i) increased funding [4]; (ii) a dramatic reduc-
tion in prices of antiretroviral medicines [5]; and (iii)
the public health approach to ART delivery [6].
Experiences on ART scale-up using the public health
approach have been reported in many RLCs, including
Ethiopia; and these reports indicated that it is possible
to scale up ART in RLCs [5,7-16].
However, the few studies which evaluated the out-
comes of large scale national ART programs in RLCs
[10,12,16] generally only included a limited number of
health facilities and patients. As a result, it will be diffi-
cult to generalize the findings to other settings. Hence,
there is a need for large-scale studies, which are con-
ducted in a wide range of health facilities and large
numbers of patients, to evaluate the outcomes of ART
programs.
The objective of this study was to evaluate the out-
comes of the rapidly expanding ART program in Ethio-
pia, which aims to provide universal access to ART,
using the commonly measured outcome indicators of
ART programs: mortality, loss to follow-up, retention in
care, change in CD4-cell counts and shift to second-line
ART [17].
Methods
The antiretroviral treatment program in Ethiopia
According to the most recent estimates, about 1 million
people (2.3% of the adult population) were living with
HIV in Ethiopia in 2009. In the same year, more than
300, 000 people needed ART [18]. A fee-based ART
program was officially started in 2003. Subsequently, a
number of initiatives have been undertaken to expand
the availability of ART in Ethiopia, including those by
the Global Fund to Fight AIDS, Tuberculosis and
Malaria, the US President’s Emergency Plan For AIDS
Relief (PEPFAR), the Ethiopian North American Health
Professionals Association, the Clinton Foundation and
the Ethiopian Red Cross Society [19]. As a result, a free
ART program was launched in early 2005. Subsequently,
ART services have been decentralized and made avail-
able at increasing numbers of both health centers and
hospitals since August 2006 [20].
The number of patients who were ever started on ART
in Ethiopia increased from 900 at the beginning of 2005
to more than 180,000 by the end of 2008, and the num-
ber of patients who were enrolled for ART increased
from 2,700 to 5,000 per month. The proportion of
patients receiving ART outside Addis Ababa increased
from 35% in 2005 to 75% in 2008 [7,8], as a result of the
free and decentralized ART program in the country [20].
The proportion of patients who received ART in health
centers increased almost 10-fold between October 2006
and October 2007, from 1.1% to 11.4% [7].
Study design
A retrospective longitudinal study was conducted to
assess the outcomes of the ART services in hospitals
and health centers from all regions and administrative
cities in the country. The study included health facilities
from both public and private sectors.
A list of all health facilities that were providing ART
services in all regions of the country (367 health facil-
ities) was used as a sampling frame. Fifty-five health
facilities (30 hospitals and 25 health centers) which were
providing ART for more than 200 patients by November
2008, the time the study was initiated, were included in
the study. Health facilities providing services for less
than 200 patients were excluded from the study because
the service delivery was relatively not well matured, and
outcomes of the services were assumed to be affected by
lack of experience. Hence, it was decided to include
health facilities with more than 200 patients on ART.
These 55 health facilities were not randomly selected.
They were selected in such a way that at least 15% of
health facilities in all regions in the country were
included, and all levels of health facilities (tertiary and
secondary hospitals and health centers) were repre-
sented. These facilities will be used as sentinel sites to
monitor the outcomes of ART program in the country.
Cohort database for ART patient monitoring was intro-
duced into the national ART program in September
2006. Hence, the study included patients who started
ART between September 2006 and August 2008. The
patient monitoring for the study ended in March 2009,
with the minimum cohort period of 6 months and the
maximum of24 months. Thus, the total study period
was 30 months.
Systematic sampling technique was used to select
individual patient charts and to identify their CD4-
cell counts. Two hundred patient charts were selected
from health facilities with more than 1000 patients on
ART, and 150 patient charts from health facilities
with 200-1000 patients on ART. These sample sizes
for number of charts were determined based on the
recommendation of WHO’s Annual Patient Monitor-
ing [17]. The charts of patients who were retained
after 24 months on ART, and had their CD4 -cell
counts determined at baseline, 6, 12 and 24 months
o nA R Tw e r eu s e dt oe x a m i n et h et r e n di nt h eC D 4 -
cell counts.
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The first-line ART regimen used consists of two nucleo-
side reverse transcriptase inhibitors plus one non-
nucleoside reverse transcriptase inhibitor. Stavudine-
lamivudine-nevirapine accounted for 46%, zidovudine-
lamivudine-nevirapine for 18%, stavudine-lamivudine-
efavirenz for 23%, and zidovudine-lamivudine-efavirenz
for 13% of the patients taking ART in the country dur-
ing the study period. The second-line regimen consists
of 2 nucleoside reverse transcriptase inhibitors plus one
protease inhibitor (lopinavir/ritonavir): abacabir-didano-
sine-lopinavir/ritonavir for 24% or tenofovir-didanosine-
lopinavir/ritonavir for 76% of the patients [21].
Patients were started on ART based on clinical and
immunological criteria: World Health Organization
stage 4; stage 3 and CD4-cell count less than 350; or
CD4-cell count less than 200 cells per micro-liter of
blood [21]. Patients had their chemistry, hematology
and CD4-cell counts determined before ART initiation
and every 6 months afterwards. Patients might have
their CD4-cell counts determined whenever necessary.
However, the CD4-cell counts were recorded in the reg-
ister for those at baseline, 6, 12 and 24 months on ART.
The time margin to document the CD4-cell counts was
one week before and after the date of appointment for
the routine CD4-cell counts at baseline, 6, 12 and 24
months on ART. Patients who were eligible for ART
would pass through both group and individual counsel-
ing sessions for ART adherence, and would then be
appointed for ART initiation after 2 weeks. They were
also screened for active opportunistic infections (OIs),
such as tuberculosis; and patients with active OIs were
treated according to the national guidelines [21].
All patients who received nevirapine-based ART were
scheduled to return 2 weeks after ART initiation for
review and dose escalation, unless contraindicated. Once
patients were started on ART, they were scheduled to
have visits every 2 weeks for the first month, every
month for the first 3 months, and every 3 months after-
ward, unless they encountered problems [21].
Data collection
Data were collected from patient registers, a hybrid of
electronic and paper-based patient management systems,
on mortality, loss to follow-up, transfer in and out, func-
tional status and regimen change to second-line treat-
ment. Patients die either at health facilities or in the
community. Mortality data for patients who died at
health facilities were collected from patient charts and
registers; and, for patients who died in the community
mortality data was collected through home visits and
telephone call of family members. Clinical charts were
used to collect the data on CD4-cell counts. The data
on CD4-cell counts were entered into a separate
database for analysis, and the median and inter-quartile
(IQ) CD4-cell counts were determined.
Measurements and statistical analysis
Mortality, loss to follow-up, retention, functional status,
median CD4-cell counts and shift to second-line ART
regimen were primary outcomes for this study and were
determined at baseline, after 6, 12, and 24 months on
ART. Data were entered, coded, cleaned and analyzed
using EPI-Info 2002 statistical software.
Ethics
Federal HIV/AIDS Prevention and Control Office of
Ethiopia coordinates the HIV/AIDS response in the
country. The Office has got an Institutional Review
Committee which reviews operational studies related to
HIV/AIDS. Our research proposal was reviewed by the
committee, and we got an approval to conduct the
study.
Results
We found that 37,466 patients were started on ART at
least 6 months prior to the censoring date. During this
6- month cohort, 2,304 (6%) patients were transferred
out to other health facilities, 125 (0.33%) patients were
shifted to second-line ART, 1,897 (5%) patients died,
5,676 (15%) patients were lost to follow-up, and 29,893
(80%) patients were alive and on ART (Table 1).
Of the 27,061 patients who were followed for 12
months. 2,511 (9%) were transferred out to other facil-
ities, 158 (0.58%) were shifted to second-line ART, 1,716
( 6 % )d i e d ,5 , 2 6 6( 2 0 % )w e r el o s tt of o l l o w - u p ,a n d
20,079 (74%) were alive and on ART (Table 1).
Out of the 7,451 patients who were in the 24-months
cohort, 882 (12%) were transferred out to other facilities,
159 (2.13%) were shifted to second-line ART, 619 (8%)
died, 1,763 (24%) were lost to follow-up, and 5,069
(68%) were alive and on ART (Table 1).
We also found that the proportion of patients who
shifted to second line treatment remained very low and
progressed slowly, from 0.33% after 6 months on ART
to 0.58% and 2.13% after 12 and 24 months on ART,
respectively (Table 1).
We found that retention rates varied considerably
among health facilities, ranging from 51% to 85% after
24 months on ART. We also found that the retention
rates after 24 months on ART in health facilities with
200-500 (34 health facilities), 500-1000 (10 health facil-
ities), 1000-2000 (7 health facilities) and greater than
2000 (4 health facilities) patients ever started on ART
are not different (Figure 1). There was also no difference
in retention rates in ART clinics in big urban cities
(with median (IQ) retention rates of 70.8 (64.3-74.5))
and rural areas (with median (IQ) retention rates of 67.2
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in retaining patients in care in the different geographical
zones (North, Central, South, West and East) of the
country where different implementing partners are sup-
porting the ART delivery.
The trend in median CD4-cell counts was drawn
based on patients retained after 24 months on ART
(5,069 patients) and had their CD4-cell counts deter-
m i n e da tb a s e l i n e ,6 ,1 2a n d2 4m o n t h so nA R T( 4 , 4 1 0
patients (87%)). Accordingly, the median CD4-cell
counts was 125 (IQ, 68-189) cells per micro-liter at
baseline, and it increased to 242 (IQ, 161-343), 269 (IQ,
185-380) and 316 (IQ, 226-445) cells per micro-liter
after 6, 12 and 24 months on ART, respectively (Figure
2). Total CD4-cell count rose by 193 cells during the 24
months of treatment, out of which 61% (117 cells per
micro-liter) was achieved during the first 6 months of
treatment, compared to only 14% (27 cells) during the
second 6 months of the first year of treatment and only
25% (47 cells) during the second year of treatment. The
proportion of patients with CD4-cell count above 200
cells per micro-liter was 21% at baseline, and it
increased to 63%, 70% and 81% after 6, 12 and 24
months on ART, respectively.
The proportion of patients that had a “working func-
tional status” at baseline was 60%, and this increased to
84%, 86% and 88% after 6, 12 and 24 months on ART,
respectively, of those still retained in care.
Discussion
This study showed that health facilities in Ethiopia were
able to retain 80%, 74% and 68% of their patients after
6, 12 and 24 months on ART, respectively. Attrition
from care and treatment sites was mainly due to loss to
Table 1 Outcomes of patients on ART in 55 health facilities in Ethiopia between September 2006 and August 2008
Duration
of cohort
Patients
in the
cohort
(a)
Transferred in
during the
cohort
(b)*
Transferred out
during the
cohort
(c)
Active
cohort
(d = a
+b-c)
Second-line ART
during the
cohort
((e) = e/d)(%)**
Died
during the
cohort
((f) = f/d)
(%)
Loss to follow-up
during the
cohort
((g) = g/d) (%)
Alive and on ART at
the end of the
cohort
(h)
6 months 38,061 1,709 2,304 (6%) 37,466 125 (0.33%) 1,897 (5%) 5,676 (15%) 29,893 (80%)
12
months
27,668 1,904 2,511 (9%) 27,061 158 (0.58%) 1,716 (6%) 5,266 (19%) 20,079 (74%)
24
months
7,519 814 882 (12%) 7,451 159 (2.13%) 619 (8%) 1,763 (24%) 5,069 (68%)
*The duration on ART of patients transferred in is calculated from the date they started ART irrespective of where they started the treatment.
**Column e is not mutually exclusive from columns f, g and h; while columns f, g and h are mutually exclusive. Patients who shifted to second-line ART during
the 6 months cohort were counted as patients on second-line ART in the 12 and 24 months cohort if they were alive and on ART after 12 and 24 months on
ART. Moreover, patients on second-line ART during the 12 months cohort were also counted as patients on second-line ART in the 24 months cohort if they were
alive and on ART after 24 months on ART.
Figure 1 Retention rates of patients after 24 months on ART.
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cohort than the other cohorts (Table 1). We found that
retention rates are variable among health facilities; but,
it does not vary with the size of the ART clinic or
patient load in the health facility (Figure 1). There were
improvements in CD4-cell counts (Figure 2) and func-
tional status of patients during the course of their treat-
ment, with enormous improvements occurring during
the first 6 months of treatment. The study also showed
that the transition to second-line treatment remained
very low and progressed slowly, from 0.33% at sixth
month to 2.13% after 24 month on ART.
Mortality and loss to follow-up rates after 6 (5% and
15%), 12 (6% and 20%) and 24 (8% and 24%) months on
ART were comparable to those in other developing
countries such as Malawi, Haiti and China [22-24]. The
high mortality and loss to follow-up in the 6-month
cohort in our study is similar to the findings in many
other studies which show that loss to follow-up and
death mostly occur during the first 6 months of treat-
ment [25-30]. Studies in Zambia and Uganda found
similarly high rates of loss to follow-up, 21% and 24%,
respectively, in the first year of ART [16,31]. This is an
indication that health facilities optimize adherence and
close patient monitoring in early months of treatment
for long-term clinical, immunological and virological
benefits for their patients.
Our study strengthens the argument that evaluations of
A R Tp r o g r a m si nR L C ss h o u l dc o n s i d e rn o to n l yt h e
number of new patients started on ART, but also the
number of patients retained in long-term care [30]. It is
evident that patients visiting health facilities more fre-
quently have a greater increase in the median CD4-cell
count, a greater drop in the median viral load and a bet-
ter chance of long-term survival [32-34]. We think recog-
nizing and addressing the challenges of retaining patients
in care potentially contribute a lot to improving the long-
term impact of ART programs. Hence, it is imperative
that ART programs set up a system that ensures regular
follow-up of patients to care and treatment services.
ART programs can develop various strategies to help
ensure patient retention in long-term care. One possible
strategy is that programs utilize different eligibility cri-
teria to restrict provision of treatment only to patients
thought to be retained in long-term care. However, such
selection process is undesirable in public sector pro-
grams that envision universal access to ART. Identifying
and addressing the major impediments to retention may
be more appropriate than excluding patients with such
impediments. Another common measure to ensure
patient retention in HIV treatment programs involves
tracing patients who have missed an appointment [35].
However, given the large number of patients and limited
financial and human resources available in RLCs, it will
be more cost-effective to prevent loss to follow-up than
to track patients who have missed visits [35].
Treatment, care and support programs can also be
designed to provide holistic services that put emphasis
Figure 2 Trend of median CD4-cell counts of 4,410 patients on ART in 55 health facilities in Ethiopia, 2006-2008.
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vide comprehensive clinical and non-clinical services
can help to address the social, economical and contex-
tual barriers which hinder regular follow-up. In general,
we believe that identifying the barriers and facilitators
for retention in care, and capitalizing on the facilitators
and addressing the barriers can significantly increase the
coverage and effectiveness of ART programs in the
long-term.
We also looked at the shift to second-line ART in 30
hospitals which are qualified to provide these services.
We found that the shift to second-line ART was 0.33%,
0.58% and 2.13% after 6, 12 and 24 months on ART,
respectively. These rates are comparable to those in
other resource-limited settings [36], but much lower
than in China (12% and 22% after 12 and 24 months on
ART, respectively) [37]. We, thus, think that the shift to
second-line ART needs close monitoring as it may have
effect on patient outcomes.
This study has both strengths and weaknesses. One of
the strengths is that the cohort was large (55 health
facilities and 37, 466 patients on ART) and that all
regions of the country were well represented. Hence, the
findings from the study can be generalized to other
health facilities in the country. The second strength of
the study is that it included many outcome indicators:
mortality, loss to follow-up, retention, transfer out,
CD4-cell count, functional status, and shift to second-
line treatment.
The first weakness of the study is that loss to follow-
up and transfer out rates are high, and as such, the out-
come for these patients is not known. It is possible that
patients who were lost to follow-up might have died, in
which case the survival benefit would have been over-
estimated. For patients who were transferred to another
treatment site, it could be argued that their outcomes
would be similar to those who remained in the same
facility where they started treatment; however, it might
not be the case. The second weakness of the study is
that the data for CD4-cell counts were not complete
either because they were not determined, or if deter-
mined, not registered. In spite of these weaknesses, this
study provides good insights into the performance of
the Ethiopian national ART program highlighting that
retention of patients in care in Ethiopia is comparable
to that of other RLCs, remains a major challenge and
varies across health facilities.
Conclusion
The ART program in Ethiopia has provided both survi-
val and immunological benefits to many PLwHAs, and
its outcomes are similar to those of ART programs in
other countries. The first 6 months of ART is so cru-
cial that program managers and service providers
should give due attention during this early course of
treatment. Retention of patients in care remains a
major challenge, and it is highly variable among health
facilities, with high, medium and low retention rates.
We, therefore, recommend further studies to analyse
and compare the characteristics (structural and process
factors) of health facilities with high, medium and low
retention rates. Moreover, early initiation of patients
on ART should be considered seriously as many
patients were started on ART late in the course of
their disease: 79% of patients on ART had baseline
CD4-cell counts less than 200 cells per micro-liter.
Finally, the shift to second-line ART warrants close
monitoring to make sure that patients are not taking a
failed regimen.
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